Outcomes In order to assess treatment effects on cardiovascular risk, the current analyses expanded upon the evaluation of changes in blood pressure and lipid parameters that have been previously reported [25, 26], and added evaluation of additional biomarkers of CV risk (ApoB, ApoC3, NT-pro-BNP, hsCRP and IL-6) in participants who received placebo, dulaglutide, or orforglipron during the T2D and obesity trials
ArdorComm Media News Network April 2, 2026 The Government of India has issued a comprehensive advisory on GLP-1 drugs, cautioning against their inappropriate use while acknowledging their growing role in managing type 2 diabetes and obesity
The choice of covariance structure (compound symmetry, autoregressive or unstructured) for the respective parameter were based on the smallest Akaike information criterion for a finite sample size (AICC)
When that vendor disappears, your research stops
(2) Tkalcevi VI, Cuzi S, Brajsa K, Mildner B, Bokuli A, Situm K, Perovi D, Glojnari I, Parnham MJ
